20 comments

[ 3.1 ms ] story [ 41.2 ms ] thread
So I’m not a biochemist or an MD or similar but this seems to say that they think they found which pre existing human antibody targets a particular covid 19 protein. And since that antibody (like all antibodies) is really hard to manufacture, someone now needs to develop a drug with a similar enough shape to do the same job (while also being non toxic and stable in the body).

We’re already harvesting antibodies from people who produce them (people who had covid and recovered) and using them to treat (or prevent) covid in others. But that’s expensive so it’s strictly for those who can pay...

Not exactly, but on the right line of thought. Antibody drugs are a common type of drug (think humira) thatbaremt that hard to manufacture (compared to something like a gene therapy). And their platform is an antibody design platform, so they've used it to design and screen antibodies to find one that will bind to and neutralize the covid virus. They're not the only ones either, there have been a few discovered so far. The next steps are to move them into clinical trials just producing these antibodies as the drug, no need for finding anything with a similar shape
> is expected to be able to produce up to two hundred thousand doses per month and the Company intends to produce a million doses at risk while seeking FDA approval

"Is expected" might be the caveat, but does sound promising from a scale perspective.

Yeah, I wondered about that: is one dose enough for complete treatment 1 person or is it one "pill" and patients need X pills per day for Y days?
(comment deleted)
>"...expected to be able to produce up to two hundred thousand doses per month "

When the cases are growing 25K/day in the US, so that many new cases in 8 days, it'll take some real testing & focus to start to catch up, but could definitely help for front-line workers. Presumably, if it really works well, could also use/build other production facilities, but it takes time.

Maybe also defense production act to swap other production lines to produce either this antibody or one of the many other candidates also announced. Although obviously I think the people taking humira or an anticancer antibody or any of the other antibodues might have some thoughts on their drug not being available so a covid drug can be made available...
I'm only a layman, but is not true that in vitro results are hardly worth getting excited about?
It depends on the in vitro experiment and the context. Something like "kills cancer cell" is nearly meaningless (hence the famous XKCD comic). Here, this is a well known mechanism of action (remember balto and the diphtheria antitoxin and the Iditarod? This is fancy antitoxin kind of). And the in vitro experiment is a test to show that it is a neutralizing antibody that binds to the virus and stops entry. The in vitro model is the exact same mechanism of entry the virus uses in the body. While there are still lots of unknowns and unknown unknowns, and of course sorrento will have to run through extensive (or perhaps less extensive under the circumstances) clinical testing before we know for sure it works, this is more promising than your usual popsci "strawberry shortcake kills cancer cells on vitro" experiment. We also have some human data from convalescent sera I believe, amd this is essentially just controlled, high quality convalescent sera that you dont need to extract from humans, so even more validation there, which is why so many people are excited about and pursuing and antibody approach (sorrento isn't the only one or the first to develop a neutralizing antibody to covid)
Misleading title. They found an inhibitor not a cure. The solution would more akin to a nasal spray that prevents infection than a therapeutic avenue.
An Inhibitor is a cure, like convalescent plasma. You could maybe use these for passive immunity, but this is clearly pitched as a therapy, not a preventative, with the idea if stopping disease progression by stopping viral replication. And I dont think antibodies can be administered nasally, they're usually injected or intravenous
(comment deleted)
Control-f on "cure". Nothing. Very misleading title.
It's a treatment that stops viral replication within four days. It might not shut down cytokine storm, but if administered earlier, it stops replication which would be a cure if it works. Biotechs tend to avoid the word cure early on, you'll see the word treatment, because cure is a word that's hard to define and often meaningless or with blurry boundaries.
> Among the antibodies showing neutralizing activity, one antibody stood out for its ability to completely block SARS-CoV-2 infection of healthy cells in the experiments. STI-1499 completely neutralized the virus infectivity at a very low antibody dose, making it a prime candidate for further testing and development. Initial biochemical and biophysical analyses also indicate STI-1499 is a potentially strong antibody drug candidate.

https://investors.sorrentotherapeutics.com/node/11241/pdf

This is as far from a "cure" or "treatment" as the Wright Brothers were from Apollo 11. In vitro results are a necessary, but insufficient path along the trajectory of developing a drug.

Heck, this press release doesn't even mention in vivo experiments. Everything is on cells. Drug development is absolutely littered with the corpses of promising in vitro studies.

Calling the experiments have have been run anything other than "preliminary work" is misleading.

this is not a cure, but mAb therapies are a very promising approach for a therapy, particularly because the basic idea already is known to work well, there's been some encouraging preliminary work, and it looks like a good target.

Sorrento are by no means the only people working on this: it's by far the most promising approach we have to give us some breathing room to get a vaccine out.

more mAb reading:

- https://blogs.sciencemag.org/pipeline/archives/2020/05/15/go...

- https://blogs.sciencemag.org/pipeline/archives/2020/04/27/mo...

- https://blogs.sciencemag.org/pipeline/archives/2020/05/06/de...

Aren't mAb therapies very expensive, though? My experience in oncology tells me that some mAb courses (bevacizumab, for example) have costs that go through the roof.
Just seeing the incredible speed that potential treatments and vaccines have arrived at testing and the accelerated pace they're being put through testing... it makes you realize that in normal time we are operating nowhere near the speed that we could be in tackling other diseases.

I wonder if this experience will change the pace of what people view as possible, like the pharmaceutical version of the Roger Bannister Effect. https://hbr.org/2018/03/what-breaking-the-4-minute-mile-taug...